

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1600RXA

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1 Web Page for STN Seminar Schedule - N. America  
NEWS 2 AUG 15 CAOLD to be discontinued on December 31, 2008  
NEWS 3 OCT 07 EPFULL enhanced with full implementation of EPC2000  
NEWS 4 OCT 07 Multiple databases enhanced for more flexible patent  
number searching  
NEWS 5 OCT 22 Current-awareness alert (SDI) setup and editing  
enhanced  
NEWS 6 OCT 22 WPIDS, WPINDEX, and WPIX enhanced with Canadian PCT  
Applications  
NEWS 7 OCT 24 CHEMLIST enhanced with intermediate list of  
pre-registered REACH substances  
NEWS 8 NOV 21 CAS patent coverage to include exemplified prophetic  
substances identified in English-, French-, German-,  
and Japanese-language basic patents from 2004-present  
NEWS 9 NOV 26 MARPAT enhanced with FSORT command  
NEWS 10 NOV 26 MEDLINE year-end processing temporarily halts  
availability of new fully-indexed citations  
NEWS 11 NOV 26 CHEMSAFE now available on STN Easy  
NEWS 12 NOV 26 Two new SET commands increase convenience of STN  
searching  
NEWS 13 DEC 01 ChemPort single article sales feature unavailable  
NEWS 14 DEC 12 GBFULL now offers single source for full-text  
coverage of complete UK patent families  
  
NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,  
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.  
  
NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS LOGIN Welcome Banner and News Items  
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that  
specific topic.

All use of STN is subject to the provisions of the STN Customer  
agreement. Please note that this agreement limits use to scientific  
research. Use for software development or design or implementation  
of commercial gateways or other similar uses is prohibited and may  
result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 11:45:10 ON 15 DEC 2008

=> fil reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 11:45:27 ON 15 DEC 2008  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 12 DEC 2008 HIGHEST RN 1083471-57-1  
DICTIONARY FILE UPDATES: 12 DEC 2008 HIGHEST RN 1083471-57-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.


Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and  
predicted properties as well as tags indicating availability of  
experimental property data in the original document. For information  
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\QUERIES\10509162.str



chain nodes :

7 8 9 10 11 12 13 14 15 21 22

ring nodes :

1 2 3 4 5 6 16 27 28 29 30 31

chain bonds :

1-14 7-8 8-9 9-10 10-11 10-21 11-12 12-13 13-22 14-15 15-16

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 16-27 16-31 27-28 28-29 29-30 30-31

exact/norm bonds :

1-2 1-6 1-14 2-3 3-4 4-5 5-6 7-8 8-9 9-10 10-11 10-21 11-12 12-13  
13-22

exact bonds :  
 14-15 15-16  
 normalized bonds :  
 16-27 16-31 27-28 28-29 29-30 30-31  
 isolated ring systems :  
 containing 1 : 16 :


Match level :  
 1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:CLASS 7:CLASS 8:CLASS 9:CLASS  
 10:CLASS 11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 18:CLASS  
 21:CLASS 22:CLASS 27:CLASS 28:CLASS 29:CLASS 30:CLASS 31:CLASS  
 Element Count :  
 Node 22: Limited  
   S,S0-1  
   O,O0-1  
   N,N0  
   C,C4

L1       STRUCTURE UPLOADED

=> d

L1 HAS NO ANSWERS

L1       STR



Structure attributes must be viewed using STN Express query preparation.

```

=> s l1
SAMPLE SEARCH INITIATED 11:46:07 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -      233 TO ITERATE

100.0% PROCESSED      233 ITERATIONS      15 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:   3745 TO      5575
PROJECTED ANSWERS:      68 TO       532

L2      15 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 11:46:13 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -      4237 TO ITERATE

100.0% PROCESSED      4237 ITERATIONS      236 ANSWERS
SEARCH TIME: 00.00.01

L3      236 SEA SSS FUL L1


=> s l3 and caplus/lc
      61087876 CAPLUS/LC
L4      218 L3 AND CAPLUS/LC

=> s l3 not l4
L5      18 L3 NOT L4

=> d l5 1-18

```


L5 ANSWER 1 OF 18 REGISTRY COPYRIGHT 2008 ACS on STN  
 RN 1027986-17-9 REGISTRY  
 ED Entered STN: 13 Jun 2008  
 CN 5-Thiazolecarboxylic acid, 2-[[[[(3,4-dichlorophenyl)methyl]-2-morpholinyl]methyl]amino]carbonyl]amino]methyl]-4-methyl-, methyl ester (CA INDEX NAME)  
 MF C20 H24 Cl2 N4 O4 S  
 SR Other Sources  
 Database: ChemSpider (ChemZoo, Inc.)



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L5 ANSWER 2 OF 18 REGISTRY COPYRIGHT 2008 ACS on STN  
 RN 1027924-70-4 REGISTRY  
 ED Entered STN: 13 Jun 2008  
 CN Urea,  
 N-[[ (2S)-4-[[ (3,4-dichlorophenyl)methyl]-2-morpholinyl]methyl]-N'-(4H-imidazol-2-ylmethyl)- (CA INDEX NAME)  
 FS STEREOSEARCH  
 MF C17 H21 Cl2 N5 O2  
 SR Other Sources  
 Database: ChemSpider (ChemZoo, Inc.)

Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L5 ANSWER 3 OF 18 REGISTRY COPYRIGHT 2008 ACS on STN  
 RN 1026677-00-8 REGISTRY  
 ED Entered STN: 09 Jun 2008  
 CN Urea, N-[[4-[[ (3,4-dichlorophenyl)methyl]-2-morpholinyl]methyl]-N'-[(5-methyl-2-thienyl)methyl]- (CA INDEX NAME)  
 MF C19 H23 Cl2 N3 O2 S  
 SR Other Sources  
 Database: ChemSpider (ChemZoo, Inc.)



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L5 ANSWER 4 OF 18 REGISTRY COPYRIGHT 2008 ACS on STN  
 RN 1026577-81-0 REGISTRY  
 ED Entered STN: 08 Jun 2008  
 CN Urea,  
 N-[[ (2S)-4-[[ (3,4-dichlorophenyl)methyl]-2-morpholinyl]methyl]-N'-[(3-methyl-1H-1,2,4-triazol-5-yl)methyl]- (CA INDEX NAME)  
 FS STEREOSEARCH  
 MF C17 H22 Cl2 N6 O2  
 SR Other Sources  
 Database: ChemSpider (ChemZoo, Inc.)


Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L5 ANSWER 5 OF 18 REGISTRY COPYRIGHT 2008 ACS on STN  
 RN 792185-40-1 REGISTRY  
 ED Entered STN: 05 Dec 2004  
 CN 3-Furancarboxylic acid, 5-[[[[(2S)-4-[(3,4-dichlorophenyl)methyl]-2-morpholinyl)methyl]amino]carbonyl]amino]methyl]-, hydrazide (CA INDEX NAME)  
 FS STEREOSEARCH  
 MF C19 H23 Cl2 N5 O4  
 CI CCM  
 SR CA


Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L5 ANSWER 6 OF 18 REGISTRY COPYRIGHT 2008 ACS on STN  
 RN 612510-95-9 REGISTRY  
 ED Entered STN: 04 Nov 2003  
 CN Urea,  
 N-[[ (2S)-4-[(3,4-dichlorophenyl)methyl]-2-morpholinyl)methyl]-N'-[[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)methyl]- (CA INDEX NAME)  
 FS STEREOSEARCH  
 MF C17 H18 Cl2 F3 N5 O3  
 CI CCM  
 SR CA


Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L5 ANSWER 7 OF 18 REGISTRY COPYRIGHT 2008 ACS on STN  
 RN 612510-56-2 REGISTRY  
 ED Entered STN: 04 Nov 2003  
 CN 3-Furancarboxylic acid, 5-[[[[(2S)-4-[(3,4-dichlorophenyl)methyl]-2-morpholinyl)methyl]amino]carbonyl]amino]methyl]- (CA INDEX NAME)  
 FS STEREOSEARCH  
 MF C19 H21 Cl2 N3 O5  
 CI CCM  
 SR CA


Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L5 ANSWER 8 OF 18 REGISTRY COPYRIGHT 2008 ACS on STN  
 RN 612510-11-9 REGISTRY  
 ED Entered STN: 04 Nov 2003  
 CN 2-Furancarboxylic acid, 5-[[[[(2S)-4-[(3,4-dichlorophenyl)methyl]-2-morpholinyl)methyl]amino]carbonyl]amino]methyl]- (CA INDEX NAME)  
 FS STEREOSEARCH  
 MF C19 H21 Cl2 N3 O5  
 CI CCM  
 SR CA

Absolute stereochemistry.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L5 ANSWER 9 OF 18 REGISTRY COPYRIGHT 2008 ACS on STN  
RN 612510-09-5 REGISTRY  
ED Entered STN: 04 Nov 2003  
CN 1,3,4-Oxadiazole-2-carboxamide, 5-[[[[(2S)-4-[(3,4-

difluorophenyl)methyl]-2-morpholinyl)methyl]amino]carbonyl]amino]methyl]-N-(1-methylethyl)- (CA INDEX NAME)  
FS STEREOSEARCH  
MF C20 H26 F2 N6 O4  
CI COM  
SR CA

Absolute stereochemistry.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L5 ANSWER 10 OF 18 REGISTRY COPYRIGHT 2008 ACS on STN  
RN 612510-07-3 REGISTRY  
ED Entered STN: 04 Nov 2003  
CN 1,3,4-Oxadiazole-2-carboxamide, 5-[[[[(2S)-4-[(3,4-

difluorophenyl)methyl]-2-morpholinyl)methyl]amino]carbonyl]amino]methyl]-N-ethyl- (CA INDEX NAME)  
FS STEREOSEARCH  
MF C19 H24 F2 N6 O4  
CI COM  
SR CA

Absolute stereochemistry.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L5 ANSWER 11 OF 18 REGISTRY COPYRIGHT 2008 ACS on STN  
RN 612510-05-1 REGISTRY  
ED Entered STN: 04 Nov 2003  
CN 1,3,4-Oxadiazole-2-carboxamide, 5-[[[[(2S)-4-[(3,4-

dichlorophenyl)methyl]-2-morpholinyl)methyl]amino]carbonyl]amino]methyl]-N-(1-methylethyl)- (CA INDEX NAME)  
FS STEREOSEARCH  
MF C20 H26 Cl2 N6 O4  
CI COM  
SR CA

Absolute stereochemistry.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L5 ANSWER 12 OF 18 REGISTRY COPYRIGHT 2008 ACS on STN  
RN 612509-95-2 REGISTRY  
ED Entered STN: 04 Nov 2003  
CN 1,2,4-Oxadiazole-3-carboxamide, 5-[[[[(2S)-4-[(3,4-

difluorophenyl)methyl]-2-morpholinyl)methyl]amino]carbonyl]amino]methyl]-N-methyl-N-(1-methylethyl)- (CA INDEX NAME)  
FS STEREOSEARCH  
MF C21 H28 F2 N6 O4  
CI COM  
SR CA


Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L5 ANSWER 13 OF 18 REGISTRY COPYRIGHT 2008 ACS on STN  
 RN 612509-85-0 REGISTRY  
 ED Entered STN: 04 Nov 2003  
 CN Urea,  
 N-[[ (2S)-4-[(3,4-dichlorophenyl)methyl]-2-morpholinyl]methyl]-N'-[(5-methyl-3-isoxazolyl)methyl]- (CA INDEX NAME)  
 FS STEREOSEARCH  
 MF C18 H22 Cl2 N4 O3  
 CI COM  
 SR CA


Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L5 ANSWER 14 OF 18 REGISTRY COPYRIGHT 2008 ACS on STN  
 RN 612509-67-8 REGISTRY  
 ED Entered STN: 04 Nov 2003  
 CN Urea,  
 N-[[ (2S)-4-[(3,4-dichlorophenyl)methyl]-2-morpholinyl]methyl]-N'-[(1-methyl-1H-1,2,3-triazol-4-yl)methyl]- (CA INDEX NAME)  
 FS STEREOSEARCH  
 MF C17 H22 Cl2 N6 O2  
 CI COM  
 SR CA


Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L5 ANSWER 15 OF 18 REGISTRY COPYRIGHT 2008 ACS on STN  
 RN 612509-65-6 REGISTRY  
 ED Entered STN: 04 Nov 2003  
 CN Urea,  
 N-[[ (2S)-4-[(3,4-dichlorophenyl)methyl]-2-morpholinyl]methyl]-N'-(1H-1,2,3-triazol-5-ylmethyl)- (CA INDEX NAME)  
 OTHER CA INDEX NAMES:  
 CN Urea,  
 N-[[ (2S)-4-[(3,4-dichlorophenyl)methyl]-2-morpholinyl]methyl]-N'-(1H-1,2,3-triazol-4-ylmethyl)- (9CI)  
 FS STEREOSEARCH  
 MF C16 H20 Cl2 N6 O2  
 CI COM  
 SR CA


Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L5 ANSWER 16 OF 18 REGISTRY COPYRIGHT 2008 ACS on STN  
 RN 610305-38-9 REGISTRY  
 ED Entered STN: 29 Oct 2003  
 CN 1-Piperidinecarboxamide, N-cyclopropyl-4-[[[[(2S)-4-[(3,4-dichlorophenyl)methyl]-2-morpholinyl]methyl]amino]carbonyl]amino]methyl]- (CA INDEX NAME)  
 FS STEREOSEARCH  
 MF C23 H33 Cl2 N5 O3  
 CI COM  
 SR CA

Absolute stereochemistry.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*



L5 ANSWER 17 OF 18 REGISTRY COPYRIGHT 2008 ACS on STN  
 RN 610305-36-7 REGISTRY  
 ED Entered STN: 29 Oct 2003  
 CN 1-Piperidinecarboxylic acid,  
 4-[[[[(2S)-4-[(3,4-dichlorophenyl)methyl]-2-morpholinyl)methyl]amino]carbonyl]amino]methyl]-, methyl ester (CA INDEX NAME)  
 FS STEREOSEARCH  
 MF C21 H30 Cl2 N4 O4  
 CI COM  
 SR CA


Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L5 ANSWER 18 OF 18 REGISTRY COPYRIGHT 2008 ACS on STN  
 RN 610305-29-8 REGISTRY  
 ED Entered STN: 29 Oct 2003  
 CN 1-Piperidinecarboxamide, 4-[[[[(2S)-4-[(3,4-dichlorophenyl)methyl]-2-morpholinyl)methyl]amino]carbonyl]amino]methyl]-N-(1-methylethyl)- (CA INDEX NAME)  
 FS STEREOSEARCH  
 MF C23 H35 Cl2 N5 O3  
 CI COM  
 SR CA

Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

=> d his


(FILE 'HOME' ENTERED AT 11:45:10 ON 15 DEC 2008)

FILE 'REGISTRY' ENTERED AT 11:45:27 ON 15 DEC 2008

L1 STRUCTURE UPLOADED  
L2 15 S L1  
L3 236 S L1 FULL  
L4 218 S L3 AND CAPLUS/LC  
L5 18 S L3 NOT L4

=>

Uploading C:\Program Files\Stnexp\Queries\QUERIES\10509162.str




chain nodes :  
7 8 9 10 11 12 13 14 15 21 22  
ring nodes :  
1 2 3 4 5 6 16 27 28 29 30 31  
chain bonds :  
1-14 7-8 8-9 9-10 10-11 10-21 11-12 12-13 13-22 14-15 15-16  
ring bonds :  
1-2 1-6 2-3 3-4 4-5 5-6 16-27 16-31 27-28 28-29 29-30 30-31  
exact/norm bonds :  
1-2 1-6 1-14 2-3 3-4 4-5 5-6 7-8 8-9 9-10 10-11 10-21 11-12 12-13  
13-22  
exact bonds :  
14-15 15-16  
normalized bonds :  
16-27 16-31 27-28 28-29 29-30 30-31  
isolated ring systems :  
containing 1 : 16 :

Match level :  
1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:CLASS 7:CLASS 8:CLASS 9:CLASS  
10:CLASS 11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 18:CLASS  
21:CLASS 22:CLASS 27:CLASS 28:CLASS 29:CLASS 30:CLASS 31:CLASS

Element Count :  
Node 22: Limited  
S,S0-1  
O,O0-1  
N,N0  
C,C4

L6 STRUCTURE UPLOADED

=> d  
L6 HAS NO ANSWERS  
L6 STR



Structure attributes must be viewed using STN Express query preparation.

=> s 16 subset=13 full  
FULL SUBSET SEARCH INITIATED 11:49:26 FILE 'REGISTRY'  
FULL SUBSET SCREEN SEARCH COMPLETED - 236 TO ITERATE

100.0% PROCESSED 236 ITERATIONS  
SEARCH TIME: 00.00.01

57 ANSWERS

L7                    57 SEA SUB=L3 SSS FUL L6


=> s 17 and caplus/lc  
          61087876 CAPLUS/LC

L8                    53 L7 AND CAPLUS/LC

=> s 17 not 18  
L9                    4 L7 NOT L8

=> d 19 1-4


L9 ANSWER 1 OF 4 REGISTRY COPYRIGHT 2008 ACS on STN  
 RN 1026677-00-8 REGISTRY  
 ED Entered STN: 09 Jun 2008  
 CN Urea, N-[[4-[(3,4-dichlorophenyl)methyl]-2-morpholinyl]methyl]-N'-[(5-methyl-2-thienyl)methyl]- (CA INDEX NAME)  
 MF C19 H23 Cl2 N3 O2 S  
 SR Other Sources  
 Database: ChemSpider (ChemZoo, Inc.)



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L9 ANSWER 2 OF 4 REGISTRY COPYRIGHT 2008 ACS on STN  
 RN 792185-40-1 REGISTRY  
 ED Entered STN: 05 Dec 2004  
 CN 3-Furancarboxylic acid, 5-[[[[(2S)-4-[(3,4-dichlorophenyl)methyl]-2-morpholinyl]methyl]amino]carbonyl]amino]methyl]-, hydrazide (CA INDEX NAME)  
 FS STEREOSEARCH  
 MF C19 H23 Cl2 N5 O4  
 CI CCM  
 SR CA


Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L9 ANSWER 3 OF 4 REGISTRY COPYRIGHT 2008 ACS on STN  
 RN 612510-56-2 REGISTRY  
 ED Entered STN: 04 Nov 2003  
 CN 3-Furancarboxylic acid, 5-[[[[(2S)-4-[(3,4-dichlorophenyl)methyl]-2-morpholinyl]methyl]amino]carbonyl]amino]methyl]- (CA INDEX NAME)  
 FS STEREOSEARCH  
 MF C19 H21 Cl2 N3 O5  
 CI CCM  
 SR CA


Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L9 ANSWER 4 OF 4 REGISTRY COPYRIGHT 2008 ACS on STN  
 RN 612510-11-9 REGISTRY  
 ED Entered STN: 04 Nov 2003  
 CN 2-Furancarboxylic acid, 5-[[[[(2S)-4-[(3,4-dichlorophenyl)methyl]-2-morpholinyl]methyl]amino]carbonyl]amino]methyl]- (CA INDEX NAME)  
 FS STEREOSEARCH  
 MF C19 H21 Cl2 N3 O5  
 CI CCM  
 SR CA

Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

=> fil caplus  
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	278.44	278.65

FILE 'CAPLUS' ENTERED AT 11:50:57 ON 15 DEC 2008  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 15 Dec 2008 VOL 149 ISS 25  
FILE LAST UPDATED: 14 Dec 2008 (20081214/ED)


Caplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

L10 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN  
ACCESSION NUMBER: 2003:943826 CAPLUS  
DOCUMENT NUMBER: 142:56365  
TITLE: Preparation of morpholinylmethylureas for use in pharmaceutical compositions as chemokine CCR-3 receptor antagonists  
INVENTOR(S): Cook, Caroline Mary; Eldred, Colin David; Harrison, Lee Andrew  
PATENT ASSIGNEE(S): Glaxo Group Limited, UK  
SOURCE: PCT Int. Appl., 52 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003099798	A1	20031204	WO 2003-EP5597	20030526
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2003240730	A1	20031212	AU 2003-240730	20030526
PRIORITY APPLN. INFO.:			GB 2002-12357	A 20020529
			WO 2003-EP5597	W 20030526

OTHER SOURCE(S): MARPAT 142:56365  
GI



AB Morpholinylmethylureas, such as I [R1 = aryl, heteroaryl, cycloalkyl, arylmethyl, heteroarylmethyl, etc.], were prepared for therapeutic use as chemokine CCR-3 receptor antagonists and are claimed for use in the treatment of inflammatory conditions, such as asthma or rhinitis. Thus,

I (R1 = Ph) was prepared via a reaction of the corresponding propynylurea I (R1 = H) with iodobenzene using (PPh3)2PdCl2, copper iodide, PPh3 and

Et3N in DMF. The prepared morpholinylmethylureas were assayed for CCR-3 binding

activity and for their inhibitory effect on eosinophil chemotaxis.


IT 808742-58-7P  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU

L10 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN  
ACCESSION NUMBER: 2003:796697 CAPLUS  
DOCUMENT NUMBER: 139:307777  
TITLE: Preparation of morpholinylmethylureas as CCR-3 antagonists  
INVENTOR(S): Ancliff, Rachael Ann; Cook, Caroline Mary; Eldred, Colin David; Gore, Paul Martin; Harrison, Lee Andrew; Hayes, Martin Alistair; Hodgson, Simon Teanby; Judd, Duncan Bruce; Keeling, Suzanne Elaine; Lewell, Xiao Qing; Mills, Gail; Robertson, Graeme Michael;  
Swanson, Stephen; Walker, Andrew John; Wilkinson, Mark; et al.  
PATENT ASSIGNEE(S): Glaxo Group Limited, UK  
SOURCE: PCT Int. Appl., 111 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003082861	A2	20031009	WO 2003-EP3335	20030327
WO 2003082861	A3	20040311		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2480106	A1	20031009	CA 2003-2480106	20030327
AU 2003226757	A1	20031013	AU 2003-226757	20030327
EP 1487828	A2	20041222	EP 2003-745294	20030327
EP 1487828	B1	20081105		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
BR 2003008780	A	20041228	BR 2003-8780	20030327
CN 1656092	A	20050817	CN 2003-811550	20030327
JP 2005526815	T	20050908	JP 2003-580326	20030327
AT 413399	T	20081115	AT 2003-745294	20030327
IN 2004KN01402	A	20060512	IN 2004-KN1402	20040922
MX 2004PA09459	A	20050125	MX 2004-PA9459	20040928
NO 2004004448	A	20041026	NO 2004-4448	20041019
US 20060063765	A1	20060323	US 2005-509162	20050610
PRIORITY APPLN. INFO.:			GB 2002-7434	A 20020328
			GB 2003-1608	A 20030124
			WO 2003-EP3335	W 20030327

OTHER SOURCE(S): MARPAT 139:307777  
GI


L10 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)  
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(prepn. of morpholinylmethylureas for use in pharmaceutical compns. as chemokine CCR-3 receptor antagonists)  
RN 808742-58-7 CAPLUS  
CN Urea, N-[[4-[(3,4-dichlorophenyl)methyl]-2-morpholinyl]methyl]-N'-[3-(2-thienyl)-2-propyn-1-yl]- (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L10 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




AB Title compds. I [R1 = (un)substituted heteroaryl; Y = bond, (un)substituted alkylene; R2 = (un)substituted aryl, heteroaryl; R3-R6 = H, alkyl] and salts and solvates thereof are CCR-3 antagonists and are thus indicated to be useful in therapy. Thus, (S)-I [Y = CH2, R1 = 5-methylcarbamoyl-1,2,4-oxadiazol-3-yl, R2 = 3,4-Cl2C6H3, R3-R6 = H] had fpKi 8.8 in the eosinophil chemotaxis test.

IT 612510-87-9P  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of morpholinylmethylureas as CCR-3 antagonists)

RN 612510-87-9 CAPLUS  
CN 3-Thiophenecarboxamide, 5-[[[[[(2S)-4-[(3,4-dichlorophenyl)methyl]-2-morpholinyl]methyl]amino]carbonyl]amino]methyl]-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.




IT 612512-04-6P 612512-05-7P 612512-07-9P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of morpholinylmethylureas as CCR-3 antagonists)

RN 612512-04-6 CAPLUS  
CN 3-Furancarboxylic acid, 5-[[[[[(2S)-4-[(3,4-dichlorophenyl)methyl]-2-morpholinyl]methyl]amino]carbonyl]amino]methyl]-, hydrazide, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.

L10 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




● HC1

RN 612512-05-7 CAPLUS  
CN 3-Furancarboxylic acid, 5-[[[[(2S)-4-[(3,4-dichlorophenyl)methyl]-2-morpholinyl)methyl]amino]carbonyl]amino]methyl]-, 2-[(1,1-dimethylethoxy)carbonyl]hydrazide (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

Cl

RN 612512-07-9 CAPLUS  
CN 3-Furancarboxylic acid, 5-[[[[(2S)-4-[(3,4-dichlorophenyl)methyl]-2-morpholinyl)methyl]amino]carbonyl]amino]methyl]-, 2-formylhydrazide (CA INDEX NAME)

Absolute stereochemistry.

L10 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




IT 612510-12-0P 612510-13-1P 612510-55-1P  
612510-57-3P  
RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(preparation of morpholinylmethylureas as CCR-3 antagonists)  
RN 612510-12-0 CAPLUS  
CN 2-Furancarboxylic acid, 5-[[[[(2S)-4-[(3,4-dichlorophenyl)methyl]-2-morpholinyl)methyl]amino]carbonyl]amino]methyl]-, compd. with N,N-diethylethanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 612510-11-9  
CMP C19 H21 Cl2 N3 O5

Absolute stereochemistry.



CM 2


CRN 121-44-8  
CMP C6 H15 N



RN 612510-13-1 CAPLUS  
CN 2-Furancarboxylic acid, 5-[[[[(2S)-4-[(3,4-dichlorophenyl)methyl]-2-morpholinyl)methyl]amino]carbonyl]amino]methyl]-, ethyl ester (CA INDEX NAME)


Absolute stereochemistry.

L10 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 612510-55-1 CAPLUS  
CN 3-Furancarboxylic acid, 5-[[[[(2S)-4-[(3,4-dichlorophenyl)methyl]-2-morpholinyl)methyl]amino]carbonyl]amino]methyl]-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 612510-57-3 CAPLUS  
CN 3-Furancarboxylic acid, 5-[[[[(2S)-4-[(3,4-dichlorophenyl)methyl]-2-morpholinyl)methyl]amino]carbonyl]amino]methyl]-, compd. with N,N-diethylethanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 612510-56-2  
CMP C19 H21 Cl2 N3 O5

Absolute stereochemistry.



CM 2

CRN 121-44-8  
CMP C6 H15 N


L10 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



IT 612510-14-2P 612510-15-3P 612510-16-4P  
612510-26-6P 612510-27-7P 612510-28-8P  
612510-29-9P 612510-30-2P 612510-31-3P  
612510-45-9P 612510-46-0P 612510-47-1P  
612510-48-2P 612510-49-3P 612510-50-6P  
612510-51-7P 612510-52-8P 612510-53-9P  
612510-54-0P 612510-58-4P 612510-59-5P  
612510-79-9P 612510-80-2P 612510-81-3P  
612510-82-4P 612510-83-5P 612510-84-6P  
612510-85-7P 612510-86-8P 612510-88-0P  
612510-89-1P 612510-90-4P 612510-91-5P  
612511-22-5P 612511-23-6P 612511-24-7P  
612511-25-8P 612511-26-9P 612511-27-0P  
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of morpholinylmethylureas as CCR-3 antagonists)


RN 612510-14-2 CAPLUS  
CN 2-Furancarboxamide, 5-[[[[(2S)-4-[(3,4-dichlorophenyl)methyl]-2-morpholinyl)methyl]amino]carbonyl]amino]methyl]-N-ethyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 612510-15-3 CAPLUS  
CN 2-Furancarboxamide, 5-[[[[(2S)-4-[(3,4-dichlorophenyl)methyl]-2-morpholinyl)methyl]amino]carbonyl]amino]methyl]-N-ethyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 612510-16-4 CAPLUS  
CN 2-Furancarboxamide, 5-[[[[(2S)-4-[(3,4-dichlorophenyl)methyl]-2-




L10 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)  
morpholinyl)methyl]amino]carbonyl]amino]methyl]-N-(1-methylethyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 612510-26-6 CAPLUS  
CN 3-Furancarboxamide, 5-[[[[(2S)-4-[(3,4-dichlorophenyl)methyl]-2-morpholinyl)methyl]amino]carbonyl]amino]methyl]-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 612510-27-7 CAPLUS  
CN 3-Furancarboxamide, 5-[[[[(2S)-4-[(3,4-dichlorophenyl)methyl]-2-morpholinyl)methyl]amino]carbonyl]amino]methyl]-N-ethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 612510-28-8 CAPLUS  
CN 3-Furancarboxamide, 5-[[[[(2S)-4-[(3,4-dichlorophenyl)methyl]-2-morpholinyl)methyl]amino]carbonyl]amino]methyl]-N-(1-methylethyl)- (CA INDEX NAME)


Absolute stereochemistry.

L10 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 612510-45-9 CAPLUS  
CN 2-Thiophenecarboxamide, 5-[[[[(2S)-4-[(3,4-difluorophenyl)methyl]-2-morpholinyl)methyl]amino]carbonyl]amino]methyl]-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 612510-46-0 CAPLUS  
CN 2-Thiophenecarboxamide, 5-[[[[(2S)-4-[(3,4-difluorophenyl)methyl]-2-morpholinyl)methyl]amino]carbonyl]amino]methyl]-N-ethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 612510-47-1 CAPLUS  
CN 2-Thiophenecarboxamide, 5-[[[[(2S)-4-[(3,4-difluorophenyl)methyl]-2-morpholinyl)methyl]amino]carbonyl]amino]methyl]-N-(1-methylethyl)- (CA INDEX NAME)


Absolute stereochemistry.

L10 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 612510-29-9 CAPLUS  
CN 3-Furancarboxamide, 5-[[[[(2S)-4-[(3,4-difluorophenyl)methyl]-2-morpholinyl)methyl]amino]carbonyl]amino]methyl]-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 612510-30-2 CAPLUS  
CN 3-Furancarboxamide, 5-[[[[(2S)-4-[(3,4-difluorophenyl)methyl]-2-morpholinyl)methyl]amino]carbonyl]amino]methyl]-N-ethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 612510-31-3 CAPLUS  
CN 3-Furancarboxamide, 5-[[[[(2S)-4-[(3,4-difluorophenyl)methyl]-2-morpholinyl)methyl]amino]carbonyl]amino]methyl]-N-(1-methylethyl)- (CA INDEX NAME)


Absolute stereochemistry.

L10 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 612510-48-2 CAPLUS  
CN 2-Thiophenecarboxamide, 4-[[[[(2S)-4-[(3,4-difluorophenyl)methyl]-2-morpholinyl)methyl]amino]carbonyl]amino]methyl]-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 612510-49-3 CAPLUS  
CN 2-Thiophenecarboxamide, 4-[[[[(2S)-4-[(3,4-difluorophenyl)methyl]-2-morpholinyl)methyl]amino]carbonyl]amino]methyl]-N-ethyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 612510-50-6 CAPLUS  
CN 2-Thiophenecarboxamide, 4-[[[[(2S)-4-[(3,4-difluorophenyl)methyl]-2-morpholinyl)methyl]amino]carbonyl]amino]methyl]-N-(1-methylethyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 612510-51-7 CAPLUS  
 CN 2-Thiophenecarboxylic acid,  
 4-[[[[(2S)-4-[(3,4-difluorophenyl)methyl]-2-  
 morpholinyl)methyl]amino]carbonyl]amino]methyl]-, methyl ester (CA INDEX  
 NAME)

Absolute stereochemistry.




RN 612510-52-8 CAPLUS  
 CN 2-Thiophenecarboxylic acid,  
 4-[[[[(2S)-4-[(3,4-difluorophenyl)methyl]-2-  
 morpholinyl)methyl]amino]carbonyl]amino]methyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 612510-53-9 CAPLUS  
 CN 2-Thiophenecarboxylic acid,  
 5-[[[[(2S)-4-[(3,4-difluorophenyl)methyl]-2-  
 morpholinyl)methyl]amino]carbonyl]amino]methyl]-, methyl ester (CA INDEX  
 NAME)

Absolute stereochemistry.




RN 612510-79-9 CAPLUS  
 CN 2-Thiophenecarboxamide, 4-[[[[(2S)-4-[(3,4-dichlorophenyl)methyl]-2-  
 morpholinyl)methyl]amino]carbonyl]amino]methyl]-N-methyl- (CA INDEX  
 NAME)

Absolute stereochemistry.




RN 612510-80-2 CAPLUS  
 CN 2-Thiophenecarboxamide, 5-[[[[(2S)-4-[(3,4-dichlorophenyl)methyl]-2-  
 morpholinyl)methyl]amino]carbonyl]amino]methyl]-N-methyl- (CA INDEX  
 NAME)

Absolute stereochemistry.




RN 612510-81-3 CAPLUS  
 CN 2-Thiophenecarboxamide, 4-[[[[(2S)-4-[(3,4-dichlorophenyl)methyl]-2-  
 morpholinyl)methyl]amino]carbonyl]amino]methyl]-N-ethyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 612510-54-0 CAPLUS  
 CN 2-Thiophenecarboxylic acid,  
 5-[[[[(2S)-4-[(3,4-difluorophenyl)methyl]-2-  
 morpholinyl)methyl]amino]carbonyl]amino]methyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 612510-58-4 CAPLUS  
 CN 3-Furancarboxylic acid, 5-[[[[(2S)-4-[(3,4-difluorophenyl)methyl]-2-  
 morpholinyl)methyl]amino]carbonyl]amino]methyl]-, ethyl ester (CA INDEX  
 NAME)

Absolute stereochemistry.




RN 612510-59-5 CAPLUS  
 CN 3-Furancarboxylic acid, 5-[[[[(2S)-4-[(3,4-difluorophenyl)methyl]-2-  
 morpholinyl)methyl]amino]carbonyl]amino]methyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 612510-82-4 CAPLUS  
 CN 2-Thiophenecarboxamide, 5-[[[[(2S)-4-[(3,4-dichlorophenyl)methyl]-2-  
 morpholinyl)methyl]amino]carbonyl]amino]methyl]-N-ethyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 612510-83-5 CAPLUS  
 CN 3-Thiophenecarboxamide, 5-[[[[(2S)-4-[(3,4-difluorophenyl)methyl]-2-  
 morpholinyl)methyl]amino]carbonyl]amino]methyl]-N-(1-methylethyl)- (CA  
 INDEX NAME)

Absolute stereochemistry.




RN 612510-84-6 CAPLUS  
 CN 3-Thiophenecarboxamide, 5-[[[[(2S)-4-[(3,4-difluorophenyl)methyl]-2-  
 morpholinyl)methyl]amino]carbonyl]amino]methyl]-N-ethyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 612510-85-7 CAPLUS  
CN 3-Thiophenecarboxamide, 5-[[[[(2S)-4-[(3,4-difluorophenyl)methyl]-2-morpholinyl)methyl]amino]carbonyl]amino]methyl]-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 612510-86-8 CAPLUS  
CN 3-Thiophenecarboxamide, 5-[[[[(2S)-4-[(3,4-dichlorophenyl)methyl]-2-morpholinyl)methyl]amino]carbonyl]amino]methyl]-N-ethyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 612510-88-0 CAPLUS  
CN 3-Thiophenecarboxamide, 5-[[[[(2S)-4-[(3,4-dichlorophenyl)methyl]-2-morpholinyl)methyl]amino]carbonyl]amino]methyl]-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 612510-89-1 CAPLUS  
CN 3-Thiophenecarboxamide, 5-[[[[(2S)-4-[(1R)-1-(3,4-dichlorophenyl)ethyl]-2-morpholinyl)methyl]amino]carbonyl]amino]methyl]-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 612510-90-4 CAPLUS  
CN 3-Thiophenecarboxamide, 5-[[[[(2S)-4-[(1S)-1-(3,4-dichlorophenyl)ethyl]-2-morpholinyl)methyl]amino]carbonyl]amino]methyl]-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 612510-91-5 CAPLUS  
CN Urea, N-[[[(2S)-4-[(3,4-dichlorophenyl)methyl]-2-morpholinyl)methyl]-N'-[4-(1,3,4-oxadiazol-2-yl)-2-furanyl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 612511-22-5 CAPLUS  
CN Urea, N-[[[(2S)-4-[(3,4-dichlorophenyl)methyl]-2-morpholinyl)methyl]-N'-[2-(2-furanyl)ethyl]- (CA INDEX NAME)




RN 612511-23-6 CAPLUS  
CN Urea, N-[[[(2S)-4-[(3,4-dichlorophenyl)methyl]-2-morpholinyl)methyl]-N'-[4-(3-methyl-1,2,4-oxadiazol-5-yl)-2-furanyl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 612511-24-7 CAPLUS  
CN Urea, N-[[[(2S)-4-[(3,4-dichlorophenyl)methyl]-2-morpholinyl)methyl]-N'-[4-(3-methyl-1H-1,2,4-triazol-5-yl)-2-furanyl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 612511-25-8 CAPLUS  
CN Urea, N-[[[(2S)-4-[(3,4-dichlorophenyl)methyl]-2-morpholinyl)methyl]-N'-[4-(5-methyl-1,3,4-oxadiazol-2-yl)-2-furanyl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 612511-26-9 CAPLUS  
CN 3-Furancarboxamide, 5-[[[[(2R,5R)-4-[(3,4-dichlorophenyl)methyl]-5-methyl-2-morpholinyl)methyl]amino]carbonyl]amino]methyl]-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 612511-27-0 CAPLUS  
CN 3-Furancarboxamide, 5-[[[[(2S,5R)-4-[(3,4-dichlorophenyl)methyl]-5-methyl-2-morpholinyl)methyl]amino]carbonyl]amino]methyl]-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.

L10 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



L10 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2002:256246 CAPLUS  
DOCUMENT NUMBER: 136:294836  
TITLE: Preparation of morpholinylmethylureas for the treatment of inflammatory diseases.  
INVENTOR(S): Ancliff, Rachael Anne; Cook, Caroline Mary; Eldred, Colin David; Gore, Paul Martin; Harrison, Lee Andrew; Hodgson, Simon Teanby; Judd, Duncan Bruce; Keeling, Suzanne Elaine; Lewell, Xiao Qing; Robertson, Graeme Michael; Swanson, Stephen  
PATENT ASSIGNEE(S): Glaxo Group Limited, UK  
SOURCE: PCT Int. Appl., 86 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002026723	A1	20020404	WO 2001-GB4350	20010928
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, GR, GU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2423305	A1	20020404	CA 2001-2423305	20010928
AU 2001090146	A	20020408	AU 2001-90146	20010928
BR 2001014321	A	20030701	BR 2001-14321	20010928
EP 1324991	A1	20030709	EP 2001-970027	20010928
EP 1324991	B1	20061115		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
HU 2003003107	A2	20040301	HU 2003-3107	20010928
JP 2004509953	T	20040402	JP 2002-531107	20010928
NZ 525055	A	20040924	NZ 2001-525055	20010928
EP 1586567	A1	20051019	EP 2005-76503	20010928
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
AT 345331	T	20061215	AT 2001-970027	20010928
ES 2275729	T3	20070616	ES 2001-970027	20010928
ZA 2003002461	A	20040628	ZA 2003-2461	20030327
NO 2003001443	A	20030526	NO 2003-1443	20030328
MX 2003PA02813	A	20031015	MX 2003-PA2813	20030328
IN 2003KN00419	A	20050311	IN 2003-KN419	20030408
US 20040058907	A1	20040325	US 2003-381871	20030721
US 7157457	B2	20070102		

PRIORITY APPLN. INFO.:

GB 2000-23973	A	20000929
GB 2001-7643	A	20010327
EP 2001-970027	A3	20010928
WO 2001-GB4350	W	20010928


OTHER SOURCE(S): MARPAT 136:294836

L10 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)  
GI




AB Title compds. [I; R1 = alkyl, alkenyl, aryl, heteroaryl, (substituted) cycloalkyl, alkynyl, etc.; R2 = H, alkyl, hydroxyalkyl; R3 = H, alkyl; R1R2N = heterocyclyl; R4, R5 = H, alkyl; R6 = alkyl, alkenyl, aryl, heteroaryl, aralkenyl, cyano, etc.; X = ethylene, CR6R7; R6, R7 = H, alkyl; R6R7C = cycloalkyl; Z = bond, CO, SO2, etc.; Q = (CH2)a; Q1 = (CH2)b; a, b = 1, 2; a+b = 2, 3], were prepared Thus, [4-(3,4-dichlorobenzyl)morpholin-2-yl]methylamine (preparation given) in CH2Cl2 was treated with PhCH2NCO and after 18 h with tris(2-aminoethyl)amine polystyrene, the mixture was stirred a further 72 h to give N-benzyl-N'-[[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl]urea. Tested I bound to CCR-3 receptors with pIC50 = 4.98-7.96.  
IT 408303-81-1P 408303-82-2P 408303-95-7P 408304-06-3P 408304-07-4P  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of morpholinylmethylureas for the treatment of inflammatory diseases)

RN 408303-81-1 CAPLUS  
CN Urea, N-[[4-[(3,4-dichlorophenyl)methyl]-2-morpholinyl]methyl]-N'-(2-thienylmethyl)- (CA INDEX NAME)




RN 408303-82-2 CAPLUS  
CN Urea, N-[[4-[(3,4-dichlorophenyl)methyl]-2-morpholinyl]methyl]-N'-(2-(2-thienyl)ethyl)- (CA INDEX NAME)


L10 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 408303-95-7 CAPLUS  
CN Urea, N-[[4-[(3,4-dichlorophenyl)methyl]-2-morpholinyl]methyl]-N'-[5-[(dimethylamino)methyl]-2-furanyl]methyl]- (CA INDEX NAME)



RN 408304-06-3 CAPLUS  
CN Urea, N-[[4-[(3,4-dichlorophenyl)methyl]-2-morpholinyl]methyl]-N'-[5-[(dimethylamino)methyl]-2-thienyl]methyl]- (CA INDEX NAME)



RN 408304-07-4 CAPLUS  
CN Urea, N-[[4-[(3,4-dichlorophenyl)methyl]-2-morpholinyl]methyl]-N'-(2-furanyl)ethyl]- (CA INDEX NAME)



REFERENCE COUNT: 10  
THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE  
FORMAT

=> log y

COST IN U.S. DOLLARS

SINCE FILE  
ENTRY

TOTAL  
SESSION

FULL ESTIMATED COST

22.11

300.76

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE  
ENTRY

TOTAL  
SESSION

CA SUBSCRIBER PRICE

-2.40

-2.40

STN INTERNATIONAL LOGOFF AT 11:58:09 ON 15 DEC 2008